Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEH1 | O60930 | 1/20 | 0.41 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.37 |
| ▸ | FEN1 | P39748 | 2/20 | 0.37 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL418381 | 1.00 | RNASEH1 (0.41) | RNASEH1ERCC1FEN1ERCC4L3MBTL1 | |
| SCHEMBL10120972 | 0.90 | L3MBTL1 (0.34) | RNASEH1L3MBTL1LMNAPARP1PARP2 | |
| SCHEMBL420508 | 0.90 | RNASEH1 (0.43) | RNASEH1ERCC1FEN1ERCC4L3MBTL1 | |
| SCHEMBL420509 | 0.90 | RNASEH1 (0.43) | RNASEH1ERCC1FEN1ERCC4L3MBTL1 | |
| SCHEMBL420507 | 0.90 | RNASEH1 (0.43) | RNASEH1ERCC1FEN1ERCC4L3MBTL1 | |
| SCHEMBL420566 | 0.86 | NAMPT (0.33) | RNASEH1ERCC1FEN1ERCC4NAMPT | |
| SCHEMBL10143672 | 0.86 | NAMPT (0.33) | RNASEH1ERCC1FEN1ERCC4NAMPT | |
| SCHEMBL420565 | 0.86 | NAMPT (0.33) | RNASEH1ERCC1FEN1ERCC4NAMPT | |
| SCHEMBL420021 | 0.80 | RNASEH1 (0.49) | RNASEH1ERCC1FEN1ERCC4ACHE | |
| SCHEMBL420020 | 0.80 | RNASEH1 (0.49) | RNASEH1ERCC1FEN1ERCC4ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | VENKATRAMAN SHANKAR (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | CCND3, CDK3, CDK2 | RNASEH1 315/4885ERCC1 1084/4885FEN1 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.